Merck Wins Ruling to Block Mylan’s Copy of Zetia, Vytorin

Merck & Co. won a U.S. appeals court ruling that will prevent Mylan Inc. from selling a generic version of the Zetia and Vytorin cholesterol medicines before April 2017.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.